All the news Showing 10 of 684 articlesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources NAFLD Burden of severe liver disease due to fatty liver will more than double by 2030 Keith Alcorn / 07 December 2018 If current trends in obesity and diabetes continue, at least 520 million people will be living with non-alcoholic fatty liver disease in western Europe, China, Japan and the United States by 2030, ... NAFLD Thyroid hormone receptor agonists reduce liver fat in people with NAFLD Liz Highleyman / 29 November 2018 Thyroid hormone activation appears to be a promising approach for treating fatty liver disease, according to a pair of studies presented at the AASLD Liver Meeting this month in San Francisco. Two thyroid ... Hepatocellular carcinoma (HCC) Nivolumab works well for liver cancer patients with advanced disease Liz Highleyman / 26 November 2018 Nivolumab (Opdivo), a checkpoint inhibitor that helps the immune system fight cancer, was associated with tumour shrinkage or disease stabilisation in just over half of hepatocellular carcinoma (HCC) patients with substantial liver function ... Hepatitis C elimination Australian experience shows high DAA uptake and rapid fall in rates of HCV viraemia among people who inject drugs Michael Carter / 26 November 2018 Providing hepatitis C virus (HCV) therapy with direct-acting antivirals (DAAs) to people who inject drugs can achieve rapid reductions in community prevalence of viraemia, according to Australian research published in the Journal of Hepatology. ... Prisoners Recent incarceration increases HIV and hepatitis C risk for people who inject drugs Michael Carter / 19 November 2018 People who inject drugs (PWID) recently released from prison or jail have a substantially increased risk of acquiring infection with HIV or hepatitis C virus (HCV), according to the results of a systematic ... Treatment for people who use drugs People who inject drugs have a high hepatitis C cure rate despite imperfect adherence Liz Highleyman / 15 November 2018 Most people who inject drugs completed treatment with sofosbuvir/velpatasvir (Epclusa) and achieved sustained virological response (SVR) in a real-world setting, even if they had interruptions in therapy, according to a presentation at the AASLD ... Pan-genotypic regimens 8 weeks of Maviret cures 98% of people with hepatitis C and cirrhosis Keith Alcorn / 14 November 2018 An 8-week course of the combination of glecaprevir and pibrentasvir (Maviret) is highly effective in curing hepatitis C in people with compensated cirrhosis, across a wide range of genotypes, Robert S. Brown of ... Hepatocellular carcinoma (HCC) Aspirin use associated with lower risk of liver cancer Liz Highleyman / 13 November 2018 Taking aspirin about twice a week for five years or more may reduce the risk of developing hepatocellular carcinoma (HCC) by about half, according to research presented this week at the AASLD Liver ... Treatment outcomes Sofosbuvir/ledipasvir cures most young children with hepatitis C Liz Highleyman / 13 November 2018 Almost all young children ages 3 to 6 years with chronic hepatitis C achieved sustained virological response after 12 weeks of treatment using sofosbuvir/ledipasvir oral granules, according to findings presented at the ... Sexual transmission Hepatitis C is detectable in rectal and nasal fluid Keith Alcorn / 12 November 2018 High levels of hepatitis C virus (HCV) can be found in the rectal and nasal fluids of people with high hepatitis C viral loads even when blood is not present, Austrian researchers ... ← First12345...69Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E NAFLD Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds